Literature DB >> 29859849

Amphetamine improves mouse and human attention in the 5-choice continuous performance test.

David A MacQueen1, Arpi Minassian2, Johnny A Kenton3, Mark A Geyer1, William Perry4, Jonathan L Brigman3, Jared W Young5.   

Abstract

Non-medical use of prescription stimulants amongst college students is common, with claims of cognitive and academic benefits. The mechanism, magnitude, and pervasiveness of the cognitive enhancing effects of stimulants in healthy adults remain poorly understood however. The present study determined the effects of dextroamphetamine (D-amp) on the 5-choice continuous performance test (5C-CPT) of attention in healthy young adult humans and mice. A mixed gender sample received placebo (n = 29), 10 (n = 17) or 20 mg D-amp (n = 25) in a double-blind fashion before 5C-CPT testing. In addition, male C57BL/6J mice were trained on a touchscreen adaptation of the 5C-CPT and tested after receiving saline or D-amp (0.1, 0.3, 1.0 mg/kg; n = 8/dose). In humans, D-amp significantly improved 5C-CPT performance. Both doses improved signal detection driven by increased hit rate (reduced omissions). Both doses also improved response accuracy and reduced hit reaction time (HRT) variability. In mice, similar effects (improved signal detection, hit rate, and response accuracy) were observed at the moderate dose (0.3 mg/kg). In contrast to human participants however, no effect on HRT variability was detected in mice, with no effect on HRT in either species. Human 5C-CPT performance was consistent with prior studies and consistent with alternative CPT paradigms. The performance of C57BL/6J mice on the touchscreen 5C-CPT mirrored performance of this strain on 5-hole operant chambers. Importantly, comparable facilitation of attention with D-amp was observed in both species. The 5C-CPT provides a cross-species paradigm by which the cognitive enhancing properties of stimulants and the neural underpinnings of attention can be assessed.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ADHD; Amphetamine; Attention; Dextroamphetamine (PubChem CID: 5826); Stimulant; Translation; Vigilance

Mesh:

Substances:

Year:  2018        PMID: 29859849      PMCID: PMC6340711          DOI: 10.1016/j.neuropharm.2018.05.034

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  66 in total

1.  Elevated levels of impulsivity and reduced place conditioning with d-amphetamine: two behavioral features of adolescence in mice.

Authors:  Walter Adriani; Giovanni Laviola
Journal:  Behav Neurosci       Date:  2003-08       Impact factor: 1.912

2.  Acute administration of d-amphetamine decreases impulsivity in healthy volunteers.

Authors:  Harriet de Wit; Justin L Enggasser; Jerry B Richards
Journal:  Neuropsychopharmacology       Date:  2002-11       Impact factor: 7.853

Review 3.  The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry.

Authors:  T W Robbins
Journal:  Psychopharmacology (Berl)       Date:  2002-08-09       Impact factor: 4.530

4.  Further evidence from haplotype analysis for linkage of the dopamine D4 receptor gene and attention-deficit hyperactivity disorder.

Authors:  C L Barr; K G Wigg; S Bloom; R Schachar; R Tannock; W Roberts; M Malone; J L Kennedy
Journal:  Am J Med Genet       Date:  2000-06-12

5.  Linkage of the dopamine D4 receptor gene and attention-deficit/hyperactivity disorder.

Authors:  G A Sunohara; W Roberts; M Malone; R J Schachar; R Tannock; V S Basile; T Wigal; S B Wigal; S Schuck; J Moriarty; J M Swanson; J L Kennedy; C L Barr
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2000-12       Impact factor: 8.829

6.  The effect of methylphenidate on three forms of response inhibition in boys with AD/HD.

Authors:  Anouk Scheres; Jaap Oosterlaan; James Swanson; Sharon Morein-Zamir; Nachson Meiran; Harry Schut; Laurens Vlasveld; Joseph A Sergeant
Journal:  J Abnorm Child Psychol       Date:  2003-02

7.  Evidence for linkage of a tandem duplication polymorphism upstream of the dopamine D4 receptor gene (DRD4) with attention deficit hyperactivity disorder (ADHD).

Authors:  J T McCracken; S L Smalley; J J McGough; L Crawford; M Del'Homme; R M Cantor; A Liu; S F Nelson
Journal:  Mol Psychiatry       Date:  2000-09       Impact factor: 15.992

8.  Selective inhibition in children with attention-deficit hyperactivity disorder off and on stimulant medication.

Authors:  Anne-Claude Bedard; Abel Ickowicz; Gordon D Logan; Sheilah Hogg-Johnson; Russell Schachar; Rosemary Tannock
Journal:  J Abnorm Child Psychol       Date:  2003-06

9.  Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder.

Authors:  Stephen V Faraone; Thomas Spencer; Megan Aleardi; Christine Pagano; Joseph Biederman
Journal:  J Clin Psychopharmacol       Date:  2004-02       Impact factor: 3.153

10.  The human dopamine D4 receptor repeat sequences modulate expression.

Authors:  O Schoots; H H M Van Tol
Journal:  Pharmacogenomics J       Date:  2003       Impact factor: 3.550

View more
  13 in total

1.  Convergent observations of MK-801-induced impairment in rat 5C-CPT performance across laboratories: reversal with a D1 but not nicotinic agonist.

Authors:  Andrew J Grottick; David L MacQueen; Samuel A Barnes; Chris Carroll; Erin K Sanabria; Vishal Bobba; Jared W Young
Journal:  Psychopharmacology (Berl)       Date:  2021-01-06       Impact factor: 4.530

2.  Amphetamine alters an EEG marker of reward processing in humans and mice.

Authors:  James F Cavanagh; Sarah L Olguin; Jo A Talledo; Juliana E Kotz; Benjamin Z Roberts; John A Nungaray; Joyce Sprock; David Gregg; Savita G Bhakta; Gregory A Light; Neal R Swerdlow; Jared W Young; Jonathan L Brigman
Journal:  Psychopharmacology (Berl)       Date:  2022-02-08       Impact factor: 4.530

3.  Preclinical Evaluation of Attention and Impulsivity Relevant to Determining ADHD Mechanisms and Treatments.

Authors:  Johnny A Kenton; Jared W Young
Journal:  Curr Top Behav Neurosci       Date:  2022

4.  The Effects of Drug Treatments for ADHD in Measures of Cognitive Performance.

Authors:  Guy A Higgins; Leo B Silenieks
Journal:  Curr Top Behav Neurosci       Date:  2022

5.  Sustained attention and vigilance deficits associated with HIV and a history of methamphetamine dependence.

Authors:  Nina Pocuca; Jared W Young; David A MacQueen; Scott Letendre; Robert K Heaton; Mark A Geyer; William Perry; Igor Grant; Arpi Minassian
Journal:  Drug Alcohol Depend       Date:  2020-08-22       Impact factor: 4.492

6.  Convergent neural substrates of inattention in bipolar disorder patients and dopamine transporter-deficient mice using the 5-choice CPT.

Authors:  Jared W Young; Mark A Geyer; Adam L Halberstadt; Jordy van Enkhuizen; Arpi Minassian; Asma Khan; William Perry; Lisa T Eyler
Journal:  Bipolar Disord       Date:  2019-05-28       Impact factor: 6.744

Review 7.  Using touchscreen-delivered cognitive assessments to address the principles of the 3Rs in behavioral sciences.

Authors:  Timothy J Bussey; Lisa M Saksida; Christopher J Heath; Laura Lopez-Cruz
Journal:  Lab Anim (NY)       Date:  2021-06-17       Impact factor: 12.625

8.  EEG reveals that dextroamphetamine improves cognitive control through multiple processes in healthy participants.

Authors:  Savita G Bhakta; James F Cavanagh; Jo A Talledo; Juliana E Kotz; Lindsay Benster; Benjamin Z Roberts; John A Nungaray; Jonathan L Brigman; Gregory A Light; Neal R Swerdlow; Jared W Young
Journal:  Neuropsychopharmacology       Date:  2022-01-18       Impact factor: 8.294

9.  Moderate prenatal alcohol exposure impairs cognitive control, but not attention, on a rodent touchscreen continuous performance task.

Authors:  Sarah L Olguin; Shannon M Thompson; Jared W Young; Jonathan L Brigman
Journal:  Genes Brain Behav       Date:  2020-03-17       Impact factor: 3.449

Review 10.  Which came first: Cannabis use or deficits in impulse control?

Authors:  Linda Rinehart; Sade Spencer
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2020-08-11       Impact factor: 5.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.